Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C18H22O4 |
| Molecular Weight | 302.3649 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@H](CC1=CC=C(O)C(O)=C1)[C@H](C)CC2=CC=C(O)C(O)=C2
InChI
InChIKey=HCZKYJDFEPMADG-TXEJJXNPSA-N
InChI=1S/C18H22O4/c1-11(7-13-3-5-15(19)17(21)9-13)12(2)8-14-4-6-16(20)18(22)10-14/h3-6,9-12,19-22H,7-8H2,1-2H3/t11-,12+
| Molecular Formula | C18H22O4 |
| Molecular Weight | 302.3649 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.druglib.com/activeingredient/masoprocol/
Sources: http://www.druglib.com/activeingredient/masoprocol/
Misoprostol is an antineoplastic drug used to treat skin growths caused by sun exposure. Masoprocol is a novel antineoplastic agent was used for the treatment of actinic keratoses (precancerous skin growths that can become malignant if left untreated). Masoprocol was withdrawn from the U.S. market in June 1996. It is not known exactly how Masoprocol works. Studies have shown that masoprocol is a potent 5-lipoxygenase inhibitor and has antiproliferative activity against keratinocytes in tissue culture, but the relationship between this activity and its effectiveness in actinic keratoses is unknown. Masoprocol also inhibits prostaglandins but the significance of this action is not yet known. Symptoms of overdose or allergic reaction include bluish coloration of skin, dizziness, severe, or feeling faint, wheezing or trouble in breathing.
Originator
Sources: http://adisinsight.springer.com/drugs/800004679
Curator's Comment: Masoprocol was originally developed by Access Pharmaceuticals (now PlasmaTech Biopharmaceuticals)
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL215 Sources: http://www.druglib.com/activeingredient/masoprocol/ |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | ACTINEX Approved UseUsed for the treatment of actinic keratoses (precancerous skin growths that can become malignant if left untreated). Launch Date1992 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
14.7 μg/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/11318430 |
50 mg/kg single, intravenous dose: 50 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
MASOPROCOL plasma | Mus musculus population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
247.7 μg × min/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/11318430 |
50 mg/kg single, intravenous dose: 50 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
MASOPROCOL plasma | Mus musculus population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
135 min EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/11318430 |
50 mg/kg single, intravenous dose: 50 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
MASOPROCOL plasma | Mus musculus population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
2500 mg 1 times / day multiple, oral Highest studied dose Dose: 2500 mg, 1 times / day Route: oral Route: multiple Dose: 2500 mg, 1 times / day Sources: |
unhealthy, 48-81 years Health Status: unhealthy Age Group: 48-81 years Sex: M Sources: |
|
10 % 2 times / day multiple, topical Dose: 10 %, 2 times / day Route: topical Route: multiple Dose: 10 %, 2 times / day Sources: |
unhealthy |
Other AEs: Contact dermatitis... |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Contact dermatitis | 4 patients | 10 % 2 times / day multiple, topical Dose: 10 %, 2 times / day Route: topical Route: multiple Dose: 10 %, 2 times / day Sources: |
unhealthy |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Establishment of a first-order kinetic model of light chain-associated amyloid fibril extension in vitro. | 2002-11-19 |
|
| Concerted regulation of free arachidonic acid and hormone-induced steroid synthesis by acyl-CoA thioesterases and acyl-CoA synthetases in adrenal cells. | 2002-11 |
|
| Regulation of apoptosis through arachidonate cascade in mammalian cells. | 2002-10-25 |
|
| Bradykinin increases permeability by calcium and 5-lipoxygenase in the ECV304/C6 cell culture model of the blood-brain barrier. | 2002-10-25 |
|
| Contribution of different phospholipases and arachidonic acid metabolites in the response of gallbladder smooth muscle to cholecystokinin. | 2002-10-01 |
|
| Investigation of the role of lipoxygenase in bioactivation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in human lung. | 2002-10 |
|
| Effect of nordihydroguaiaretic acid on intracellular Ca(2+) concentrations in hepatocytes. | 2002-10 |
|
| Effect of nordihydroguaiaretic acid on the secretion of lipoprotein lipase. | 2002-09-30 |
|
| Inhibition of peroxisome proliferator-activated receptor (PPAR)-mediated keratinocyte differentiation by lipoxygenase inhibitors. | 2002-09-15 |
|
| Platelet aggregating response to platelet activating factor participates in activation of the 12-lipoxygenase pathway in platelets from rabbits. | 2002-09 |
|
| N-acylethanolamines are metabolized by lipoxygenase and amidohydrolase in competing pathways during cottonseed imbibition. | 2002-09 |
|
| Design, synthesis, and biological evaluation of a cephalosporin-monohydroguaiaretic acid prodrug activated by a monoclonal antibody-beta-lactamase conjugate. | 2002-09 |
|
| [Lipoxygenase inhibitors induce rat hepatocyte apoptosis in primary culture]. | 2002-08-30 |
|
| Neurons overexpressing mutant presenilin-1 are more sensitive to apoptosis induced by endoplasmic reticulum-Golgi stress. | 2002-08-15 |
|
| Kinetics of inhibition of leukocyte 12-lipoxygenase by the isoform-specific inhibitor 4-(2-oxapentadeca-4-yne)phenylpropanoic acid. | 2002-08-13 |
|
| Stimulatory effects of adenosine on prolactin secretion in the pituitary gland of the rat. | 2002-07 |
|
| Structure-activity relationship studies of nordihydroguaiaretic acid inhibitors toward soybean, 12-human, and 15-human lipoxygenase. | 2002-06-06 |
|
| Nordihydroguaiaretic acid-mediated inhibition of ultraviolet B-induced activator protein-1 activation in human keratinocytes. | 2002-06 |
|
| Participation of the arachidonic acid cascade pathway in macrophage binding/uptake of oxidized low density lipoprotein. | 2002-06 |
|
| Contractile response to a cannabimimetic eicosanoid, 2-arachidonoylglycerol, of longitudinal smooth muscle from the guinea-pig distal colon in vitro. | 2002-05-31 |
|
| alpha 2B-adrenergic receptor activates MAPK via a pathway involving arachidonic acid metabolism, matrix metalloproteinases, and epidermal growth factor receptor transactivation. | 2002-05-31 |
|
| Effects of brefeldin A and nordihydroguaiaretic acid on endomembrane dynamics and lipid synthesis in plant cells. | 2002-05-08 |
|
| Mechanisms underlying the activation of large conductance Ca2+-activated K+ channels by nordihydroguaiaretic acid. | 2002-05 |
|
| Nordihydroguaiaretic acid potently breaks down pre-formed Alzheimer's beta-amyloid fibrils in vitro. | 2002-05 |
|
| Involvement of glycogen synthase kinase-3beta and tau phosphorylation in neuronal Golgi disassembly. | 2002-05 |
|
| Effects of cyclooxygenase and lipoxygenase inhibition on basal- and serotonin-induced ion transport in rat colon. | 2002-05 |
|
| Mechanisms of nordihydroguaiaretic acid-induced growth inhibition and apoptosis in human cancer cells. | 2002-04-08 |
|
| [Simultaneous determination of five antioxidants in food by HPLC with fluorescence detection]. | 2002-04 |
|
| Comparative quantitative structure toxicity relationships for flavonoids evaluated in isolated rat hepatocytes and HeLa tumor cells. | 2002-03-20 |
|
| Structure-activity relationships for inhibition of human 5alpha-reductases by polyphenols. | 2002-03-15 |
|
| Possible implication of Golgi-nucleating function for the centrosome. | 2002-03-01 |
|
| Effects of various reactive oxygen species on the guinea pig trachea and its epithelium. | 2002-03 |
|
| Expression and induction of the stress protein alpha-B-crystallin in vascular endothelial cells. | 2002-03 |
|
| Effect of nordihydroguaiaretic acid on intracellular Ca(2+) concentrations in C6 glioma cells. | 2002-03 |
|
| Effects of inhibitors of the lipo-oxygenase family of enzymes on the store-operated calcium current I(CRAC) in rat basophilic leukaemia cells. | 2002-02-15 |
|
| Tending tender tendons. | 2002-02-08 |
|
| Arachidonic and linoleic acid metabolism in mouse intestinal tissue: evidence for novel lipoxygenase activity. | 2002-02-01 |
|
| Native LDL induces proliferation of human vascular smooth muscle cells via redox-mediated activation of ERK 1/2 mitogen-activated protein kinases. | 2002-02 |
|
| Multiple biological effects of inhibitors of arachidonic acid metabolism on human keratinocytes. | 2002-02 |
|
| 5-Lipoxygenase and human pulmonary artery endothelial cell proliferation. | 2002-02 |
|
| Evidence for the involvement of cyclooxygenase activity in the development of cocaine sensitization. | 2002-01-29 |
|
| Differential effect of brefeldin A on the palmitoylation of surfactant protein C proprotein mutants. | 2002-01-11 |
|
| Cytosolic phospholipase A2 and lipoxygenase are involved in cell cycle progression in neuroblastoma cells. | 2002-01 |
|
| The lipoxygenase pathways are involved in LH-stimulated progesterone production in bovine corpus luteum. | 2002-01 |
|
| [Effect of exogenous leukotrienes and lipoxygenase inhibitors on apoptosis and necrosis in cultured rat hepatocytes]. | 2002 |
|
| Synthesis and anticancer activity of nordihydroguaiaretic acid (NDGA) and analogues. | 2001-12 |
|
| Nordihydroguaiaretic acid elevates osteoblastic intracellular Ca2+. | 2001-12 |
|
| Progressive apoptosis in chorion laeve trophoblast cells of human fetal membrane tissues during in vitro incubation is suppressed by antioxidative reagents. | 2001-12 |
|
| Lipoxygenase inhibitors inhibit heparin-releasable lipoprotein lipase activity in 3T3-L1 adipocytes and enhance body fat reduction in mice by conjugated linoleic acid. | 2001-11-30 |
|
| Intracellular signaling pathway of FGF-2-modulated corneal endothelial cell migration during wound healing in vitro. | 2001-11 |
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10950827
Incubation of masoprocol (50 uM) with adipocytes from chow-fed rats significantly inhibited isoproterenol-induced lipolytic activity and HSL activity, associated with a decrease in the ability of isoproterenol to phosphorylate HSL. Masoprocol had no apparent effect on adipose tissue phosphatidylinositol 3-kinase activity, but okadaic acid, a serine/threonine phosphatase inhibitor, blocked the antilipolytic effect of masoprocol.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:32:55 GMT 2025
by
admin
on
Mon Mar 31 18:32:55 GMT 2025
|
| Record UNII |
7BO8G1BYQU
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C275
Created by
admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
|
||
|
NCI_THESAURUS |
C1322
Created by
admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
|
||
|
WHO-VATC |
QL01XX10
Created by
admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
|
||
|
CFR |
21 CFR 189.165
Created by
admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
|
||
|
WHO-ATC |
L01XX10
Created by
admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
BB-4
Created by
admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
|
PRIMARY | |||
|
NORDIHYDROGUAIARETIC ACID
Created by
admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
|
PRIMARY | |||
|
227239
Created by
admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
|
PRIMARY | RxNorm | ||
|
SUB08652MIG
Created by
admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
|
PRIMARY | |||
|
500-38-9
Created by
admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
|
NON-SPECIFIC STEREOCHEMISTRY | |||
|
4265
Created by
admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
|
PRIMARY | |||
|
207-903-0
Created by
admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
|
ALTERNATIVE | |||
|
27686-84-6
Created by
admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
|
PRIMARY | |||
|
682984
Created by
admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
|
PRIMARY | |||
|
248-606-6
Created by
admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
|
PRIMARY | |||
|
D009637
Created by
admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
|
PRIMARY | |||
|
C701
Created by
admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
|
PRIMARY | |||
|
71398
Created by
admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
|
PRIMARY | |||
|
7625
Created by
admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
|
PRIMARY | |||
|
4291
Created by
admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
|
PRIMARY | |||
|
7BO8G1BYQU
Created by
admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
|
PRIMARY | |||
|
6615
Created by
admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
|
PRIMARY | |||
|
1860612
Created by
admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
|
ALTERNATIVE | |||
|
m8052
Created by
admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
|
PRIMARY | Merck Index | ||
|
73468
Created by
admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
|
PRIMARY | |||
|
1637
Created by
admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
|
PRIMARY | |||
|
7BO8G1BYQU
Created by
admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
|
PRIMARY | |||
|
CHEMBL3545025
Created by
admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
|
PRIMARY | |||
|
100000081745
Created by
admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
|
PRIMARY | |||
|
DTXSID5045178
Created by
admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
|
PRIMARY | |||
|
DB00179
Created by
admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
|
PRIMARY | |||
|
CHEMBL52
Created by
admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|